Oncology, CNS Agents May Dominate 2006 NME Approvals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb’s multi-targeted kinase inhibitor dasatinib and Genta’s Bcl-2 inhibitor Genasense (oblimersen) could be approved for leukemia indications in the first half of 2006, if granted priority reviews. Both agents were submitted in late December.